Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04192565
Other study ID # CMX-CSP-CS002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2020
Est. completion date March 29, 2021

Study information

Verified date June 2021
Source ColubrisMX
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, single-arm, open-label, multi-center, feasibility study to evaluate the safety and efficacy of ColubrisMX ELS System in patients undergoing transanal endoluminal procedures, specifically colorectal Endoscopic Submucosal Dissection.


Description:

Current treatment options for colorectal lesions most often include flexible endoscopy or open/laparoscopic surgery. Both approaches have procedural limitations that can have considerable impact on patient care. Traditional endoscopic tools have technical inadequacies, ones that inhibit the physician's ability to complete more complex tasks consistent with a surgical technique. Conversely a traditional open or laparoscopic surgical approach involves increased chance of complications (such as surgical site infection), more pain & blood loss, longer recovery and larger surgical scars. This clinical study proposes the use of an endoluminal robotic technology that is designed to improve patient outcomes for colorectal lesions. This system allows physicians to perform many types of complex endoluminal procedures with more precision, flexibility, and control than that of conventional endoscopic, open or laparoscopic surgical techniques. Using this robotic system, surgeons can perform delicate and complex endoluminal procedures that may have been difficult or impossible with other methods, and could have positive impact on outcomes, recovery time, and overall patient care. Patients will undergo the procedure using the ColubrisMX ELS System, and its initial safety and efficacy outcomes will be assessed intraoperatively and postoperatively at discharge and days 7 and 30.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date March 29, 2021
Est. primary completion date March 29, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility 13 INCLUSION CRITERIA All of the following criteria must be present to be eligible for the study: 1. Aged 18-75 years 2. BMI = 35 kg/m2 3. Patient agrees to participate in the study by giving signed informed consent 4. Benign lesions of the rectum, such as adenoma, submucosal nodule, or polyp 5. Mucosal neoplasm 6. Eligible to undergo standard endoscopic submucosal dissection. 7. Patient reviewed and approved by Local Oncology Committee to undergo robotic procedure. 14 EXCLUSION CRITERIA Patients will be excluded from the study if any of the following criteria are present: Preoperative 1. Anatomy unsuitable for endoscopic visualization or endoluminal surgery 2. Extensive previous surgery in the lower GI tract 3. Prior radiation treatment for colorectal cancer 4. Patient with distant metastases 5. Untreated active infection 6. Vulnerable population (e.g., prisoners, mentally disabled) 7. Severe concomitant illness (i.e., cancer) that drastically shortens life expectancy or increases risk of therapeutic interventions 8. Breastfeeding or pregnant, or intend to become pregnant during the course of the study 9. Currently enrolled in or discontinued within the last 30 days from a clinical trial of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study 10. In the opinion of the Investigator, the patient is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. 11. Patients with immunosuppression drugs (chemotherapy) due to an increase potential infection and poor healing 12. Patients with a high cardiac or pulmonary risk (these patients require clearance from a cardiologist and pulmonologist) 13. Preoperative blood thinner i.e., coumadin or heparin. 14. Obstructing rectal cancer 15. History of inflammatory bowel disease

Study Design


Intervention

Device:
Robotic Endoluminal Resection
Robotic Resection of mucosal neoplasms in the colon and rectum using the ColubrisMX ELS system

Locations

Country Name City State
Brazil Faculdade de Medicina do ABC Santo André Sao Paulo

Sponsors (2)

Lead Sponsor Collaborator
ColubrisMX Faculdade de Medicina do ABC

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of success Percentage of patients with no conversion during surgery and no major complications (Clavien-Dindo = 3 complication rate) 24 hours post-op
Primary Rate of Conversion Percentage of patients with a change in treatment plan to a conventional open or laparoscopic procedure Intraoperative
Primary Complication rate (%) Percentage of patients having Clavien-Dindo = 3 Intraoperatively and postoperatively at Days 7 and 30.
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A
Terminated NCT00950820 - Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer Phase 2